| Phase 19 trials |
|
Phase 1
|
NCT06793956 |
Feb 2025 → Jan 2026 overdue |
extranodal nasal NK/T cell lymphoma |
Sun Yat-sen University |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06712173 |
Dec 2024 → Sep 2025 overdue |
peripheral T-cell lymphoma, not otherwise specified |
Institute of Hematology & Blood Diseases Hospital, China |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT05676710 |
Feb 2023 → Jan 2024 |
T-cell large granular lymphocyte leukemia |
Institute of Hematology & Blood Diseases Hospital, China |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05676697 |
Jan 2023 → Jan 2024 |
autoimmune hemolytic anemia |
Institute of Hematology & Blood Diseases Hospital, China |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT05429398 |
Jun 2022 → Aug 2023 |
neoplasm |
Shanghai YingLi Pharmaceutical Co. Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 1
|
NCT04279405 |
Jun 2020 → Sep 2021 |
chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, lymphoplasmacytic lymphoma, mantle cell lymphoma +1 |
Shanghai YingLi Pharmaceutical Co. Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04108325 |
Mar 2020 → Jun 2021 |
peripheral T-cell lymphoma, not otherwise specified |
Shanghai YingLi Pharmaceutical Co. Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 1
|
NCT04049929 |
Aug 2019 → Oct 2020 |
neoplasm |
Shanghai YingLi Pharmaceutical Co. Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 1
|
NCT03757000 |
Dec 2017 → Mar 2019 |
B-cell chronic lymphocytic leukemia |
Shanghai YingLi Pharmaceutical Co. Ltd. |
Unknown
|
No outcome recorded
|
| Phase 1/212 trials |
|
Phase 1/2
|
NCT07209163 |
Oct 2025 → Mar 2026 overdue |
peripheral T-cell lymphoma, not otherwise specified |
Ruijin Hospital |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT07139353 |
Sep 2025 → Sep 2027 expected |
peripheral T-cell lymphoma, not otherwise specified |
Sun Yat-sen University |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT06981988 |
Jun → Aug 2025 overdue |
non-Hodgkin lymphoma |
Jiangsu HengRui Medicine Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT06799676 |
Feb 2025 → Aug 2027 expected |
plasma cell myeloma |
Fuling Zhou |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT06592170 |
Aug 2024 → Aug 2025 overdue |
lymphoma |
The First Hospital of Jilin University |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT06421948 |
May 2024 → May 2027 expected |
peripheral T-cell lymphoma, not otherwise specified |
Yanyan Liu |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT06376721 |
Apr 2024 → Oct 2026 expected |
T-lymphoblastic lymphoma, extranodal nasal NK/T cell lymphoma |
Beijing Tongren Hospital |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT06083701 |
Sep 2023 → Sep 2024 |
peripheral T-cell lymphoma, not otherwise specified |
Peking Union Medical College Hospital |
Unknown
|
No outcome recorded
|
|
Phase 1/2
|
NCT05949944 |
Aug 2023 → Aug 2026 overdue |
peripheral T-cell lymphoma, not otherwise specified |
Sun Yat-sen University |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT06037239 |
Jul 2023 → Jul 2024 |
lymphoma |
Peking Union Medical College Hospital |
Unknown
|
No outcome recorded
|
|
Phase 1/2
|
NCT05559008 |
Sep 2022 → Mar 2024 |
peripheral T-cell lymphoma, not otherwise specified |
Ruijin Hospital |
Unknown
|
No outcome recorded
|
|
Phase 1/2
|
NCT04500561 |
Aug 2020 → Oct 2021 |
diffuse large B-cell lymphoma |
Shanghai YingLi Pharmaceutical Co. Ltd. |
Unknown
|
No outcome recorded
|
|
| Phase 213 trials |
|
Phase 2
|
NCT07031115 |
Sep → Dec 2025 overdue |
primary acquired red cell aplasia |
Peking Union Medical College Hospital |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07195799 |
Dec 2024 → Dec 2027 expected |
non-Hodgkin lymphoma |
The First Affiliated Hospital with Nanjing Medical University |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06530550 |
Aug 2024 → Aug 2026 overdue |
T-cell large granular lymphocyte leukemia, chronic lymphoproliferative disorder of NK-cells |
Institute of Hematology & Blood Diseases Hospital, China |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06489808 |
May 2024 → Dec 2026 expected |
aggressive B-cell non-Hodgkin lymphoma |
Institute of Hematology & Blood Diseases Hospital, China |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06324994 |
May 2024 → May 2025 overdue |
mantle cell lymphoma |
Dalian Medical University |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06224257 |
Dec 2023 → Oct 2025 overdue |
T-cell large granular lymphocyte leukemia |
Institute of Hematology & Blood Diseases Hospital, China |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06347653 |
Nov 2023 → Jan 2027 expected |
Nodal T-follicular helper cell lymphoma, follicular type |
Peking University |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06158386 |
Nov 2023 → Dec 2027 expected |
follicular lymphoma |
The First Affiliated Hospital of Xiamen University |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05274997 |
May 2022 → Jan 2023 |
mature T-cell and NK-cell non-Hodgkin lymphoma |
Shanghai YingLi Pharmaceutical Co. Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 2
|
NCT04948788 |
Oct 2021 → Apr 2023 |
B-cell non-Hodgkin lymphoma |
Jiangsu HengRui Medicine Co., Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 2
|
NCT04705090 |
Apr 2021 → Dec 2022 |
— |
Shanghai YingLi Pharmaceutical Co. Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 2
|
NCT04379167 |
Dec 2020 → Dec 2022 |
follicular lymphoma |
Shanghai YingLi Pharmaceutical Co. Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 2
|
NCT04370405 |
Apr 2019 → Nov 2020 |
follicular lymphoma |
Shanghai YingLi Pharmaceutical Co. Ltd. |
Unknown
|
No outcome recorded
|
|
| Phase 2/31 trial |
|
Phase 2/3
|
NCT06548347 |
Sep → Dec 2024 overdue |
peripheral T-cell lymphoma, not otherwise specified |
Shanghai YingLi Pharmaceutical Co. Ltd. |
Not yet recruiting
|
No outcome recorded
|
| Phase 41 trial |
|
Phase 4
|
NCT06343935 |
Apr 2024 |
indolent B-cell non-Hodgkin lymphoma |
Shanghai YingLi Pharmaceutical Co. Ltd. |
Unknown
|
No outcome recorded
|